May 20, 2011 (San Diego, CA) — The platelet-function test VerifyNow P2Y12 (Accumetrics), has been granted a CE mark in Europe for a new, updated claim for prognostic use to help identify patients with ...

Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to ...

An omnipresent possibility, platelet resistance is being studied more closely as witnessed by the POPULAR study published during AHA. New tests such as "VerifyNow" offer us onsite methods to screen ...

Aspirin resistance — and what can be done for patients who do not respond to aspirin — has interventional cardiology abuzz. Likewise, the VerifyNow Aspirin Test from Accumetrics is emerging as an ...

SAN DIEGO, Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple ...

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow(R) System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple ...

SAN DIEGO, Nov. 19 Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was ...

Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, ...

SAN DIEGO--(BUSINESS WIRE)--Accumetrics, Inc., developer of the VerifyNow ® System, the first rapid and easy-to-use system for measuring platelet reactivity to multiple antiplatelet agents, announced ...

VerifyNow System, a point-of-care diagnostic, will be designed for use in clinical studies. Accumetrics and Portola Pharmaceuticals will together develop and supply Accumetrics’ VerifyNow System and ...